??Motor dysfunction after the first stroke
Conditions
Interventions
Control group1:Sham stimulation + modified constraint-induced movement therapy (mCIMT)
Control group3:High-precision (non-brain-network-matched) tDCS stimulation plus conventional motor therapy
Trial group:Brain-network-specific tDCS target stimulation plus conventional motor therapy
Control group2:Traditional tDCS single-target stimulation plus conventional motor therapy
Sponsors
Beijing Bo'ai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–80 years, either sex; 2. First-time unilateral supratentorial ischemic stroke, confirmed by imaging (within 1–3 months after onset); 3. Partial preservation of wrist and finger mobility: wrist extension angle >=10°; thumb abduction/extension angle >=10°; at least two other fingers with extension angle >=10°; 4. Unilateral limb weakness with a Fugl-Meyer Upper Extremity score (FM-UE) <=54 (maximum score: 66); 5. Two baseline FM-UE assessments performed 7–14 days apart (Baseline 1 and 2, referred to as B1 and B2), with a difference <=2 points between measurements, indicating stable motor impairment; if unstable, reassessment must be conducted within 7–14 days, with a maximum of three assessments allowed; 6. Pre-stroke mRS <=2; 7. MRI-compatible (no metallic implants, claustrophobia, etc.).
Exclusion criteria
Exclusion criteria: 1. Other types of stroke: hemorrhagic or brainstem lesions (primary intracerebral hemorrhage, subarachnoid hemorrhage, bilateral hemispheric or brainstem ischemic stroke); 2. Use of medications that may interfere with tDCS (transcranial direct current stimulation), including carbamazepine, flunarizine, sulpiride, rivastigmine, and dextromethorphan; 3. Moderate to severe cognitive impairment, defined by a Montreal Cognitive Assessment (MoCA) score <18; 4. Poorly controlled psychiatric disorders (e.g., depression or other psychiatric conditions), even if pharmacologically stabilized, but still potentially affecting trial participation; 5. Presence of risk factors related to MRI/tDCS/TMS; 6. Received botulinum toxin injections within the past 3 months, with injection sites in the affected upper limb.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of FM-UE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improved Barthel Index (MBI), ADL score;The change of fMRI-FC; | — |
Countries
China
Contacts
Public ContactQi Lei
Beijing Bo'ai Hospital
Outcome results
None listed